

FMHL/SE/BM/AUG'19

The General Manager

Department of Corporate Services BSE Limited PhirozeJeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 523696 **Fortis Malar Hospitals**

52, First Main Road, Gandhi Nagar, Adyar,

Chennai, Tamil Nadu – 600 020 Tel : +91 44 4289 2222 Fax : +91 44 4289 2293

Email : secretarial.malar@malarhospitals.in

Website: www.fortismalar.com

Aug 2, 2019

Sub: Outcome of the Board Meeting

Dear Sir,

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosures Requirement) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. August 2, 2019, *inter-alia*, considered and approved: -

- 1. Un-audited standalone and consolidated financial results of the Company for the quarter ended on June 30, 2019 along with limited review report thereon;
- **2.** Convening of 28th Annual General Meeting of the Company on Thursday, September 26, 2019 at National Institute of Pharmaceutical Education and Research, Sector 67, SAS Nagar Mohali- Punjab, 160062.
- 3. The Company has received a request letter ("FHsL Letter") from Fortis Hospitals Limited ("FHsL") (holding and one of the Promoters) stating that FHsL is a wholly owned subsidiary of Fortis Healthcare Limited ("FHL") and FHL, vide its letter FHL/SEC/2019-20 dated June 03, 2019 captioned "Reclassification of Promoters", intimated to stock exchanges [viz. BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE")] regarding the approval granted by the stock exchanges viz. BSE & NSE for reclassification of the following promoters as public shareholders: Malvinder Mohan Singh – Trust, Harpal Singh, Abhishek Singh, Malvinder Mohan Singh, Shivinder Mohan Singh, Fortis Healthcare Holdings Private Limited, Malav Holdings Private Ltd, RHC Holding Private Limited ("Erstwhile Promoters of FHL") and that the only remaining promoter of FHL is Northern TK Venture Pte. Limited ("NTK"). Further, Securities and Exchange Board of India ("SEBI"), had on October 17, 2018, December 21, 2018, March 19, 2019 and June 28, 2019 ("SEBI Orders"), directed that Mr. Malvinder Mohan Singh ("MMS") and Mr. Shivinder Mohan Singh ("SMS") shall not associate themselves with the affairs of FHL and FHsL in any manner whatsoever, till further directions.

FHsL, being Promoter and largest shareholder of FMHL, is holding 11752402 equity shares representing 62.71% stake. Further, other than FHsL, following entities are Promoter / Promoter Group Companies ("Identified Promoter / Promoter Group") of the Company:



Fortis Malar Hospitals

Fax

52, First Main Road, Gandhi Nagar, Adyar,

Chennai, Tamil Nadu - 600 020 Tel : +91 44 4289 2222 : +91 44 4289 2293

Email: secretarial.malar@malarhospitals.in

Website: www.fortismalar.com

		ww.ioitisiiiaiai.coiii
Sn	Name of entities to be reclassified as "public shareholder"	Number of shares held as on July 26, 2019
1	PS Trust (Acting and Represented by its trustees, Mr. Malvinder Mohan Singh and Dr. Shivinder Mohan Singh)	100
2	Fortis Healthcare Holdings Private Limited	100
3	Oscar Investments Ltd	0
4	Shivi Holdings (P) Ltd	100
5	RHC Finance Private Limited	100
6	Todays Holdings Private Limited	100
7	Malav Holdings Private Limited	0
8	RHC Holding Private Limited	0

In view of the letter received from FHsL and the facts stated herein above, the Board considered the same and empowered certain officials to issue letters to Identified Promoter / Promoter Group for intimating the decision of the Company with respect to reclassification of status of said members as public shareholders.

Please find enclosed Un-audited standalone and consolidated financial results along with limited review report for quarter ended on June 30, 2019 and a copy of the press release being issued in this regard.

The Board Meeting commenced at 1300 Hours and concluded at 1700 Hours.

This is for your information and records please.

Yours faithfully For Fortis Malar Hospitals Limited

Digitally signed by SHASHAN SHASHANK PORWAL K PORWAL Date: 2019.08.02

Shashank Porwal Company Secretary

FORTIS MALAR HÖSPITALS LIMITED (CIN: L85110PB1989PLC045948) Regd. Office: Portis Hospital, Sector 62, Phase – VIII, Mohali-160062 Tel Numbers: 0172 5096001 & Tele Fax No: 0172 5096002 Website: www.fortismalar.com; Email: secretarial.malar@malarhospitals.in STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30-JUNE-2019

Income	41	C TRIPLE OF THE PARTY OF THE PA		Standalone		Standalone		Consolidated	(No. err	Consolidated
Decrease			30-June-2019	31-March-2019	30_fune_2018	21 Moreh 2010	10 T. 1010	Quarter ended		Year ended
December			(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	31-March-2019 (Unaudited)	30-June-2018 (Unaudited)	31-March-2019 (Audited)
December		Income		(C SIGN JSISW)						
Other income 251,57 315,41 219,18 968,44 260,87 325,92 325,93 325,		a) Revenue from operations	3,187.38	3,515.34	3,356.13	14 459 39	3 187 38	3 515 34	2 366 13	00000
Purchase of medical consumables and drugs 3,438.56 3,548.15 3,448.15		b) Other income	251.57	315.41	219.18	968.44	260.87	325 93	3,356.13	14,459.39
Particles of moderal consumables and drugs 661.09 847.81 764.43 3.302.36 661.00 847.81 764.43 3.302.36 9.00.00 3.20.00 3.			3,438.95	3,830.75	3,575.31	15,427.83	3,448.25	3,841.27	3.585.94	15,470.47
9 y Precisions of medical consumables and drugs 661.09 847.81 764.43 3.30.25 661.09 847.81 764.43 3.30.25 661.09 847.81 764.43 3.30.25 661.09 847.81 764.43 3.30.25 661.09 847.81 764.43 8.30.25 61.00 861.00 847.81 142.8 65.38 5.68 11 2.34 2.34 2.30 2.34 2.34 2.34 2.34 2.34 2.34 2.34 2.34	. 3.						0			110000
5 5 5 5 5 5 5 5 5 5		a) Purchase of medical consumables and drugs	60.199	847.81	764.43	3,302.36	60.199	847.81	764 43	32 602 2
5.3.36 5.6.81 5.3.45 5.6.81 5.3.45 5.6.81 5.3.45 5.6.81 5.3.45 5.6.81 5.3.45 5.6.81 5.3.45 5.6.81 5.3.45 5.6.81 5.3.45 5.6.81 5.3.45 5.6.81 5.3.45 5.6.81 5.3.45 5.6.81 5.3.45 5.6.81 5.3.45 5.6.81 5.3.45 5.6.81 5.3.45 5.6.81 5.3.45 5.6.81 5.3.45 5.0.81 5.0.81 5		of Changes in inventories of medical consumables and drugs	14.28	(2.98)	3.57	37.43	14.28	(2 98)	3.57	37.43
1968 at 20 20 20 20 20 20 20 20		c) Employee benefits expense	553.36	556.81	571.73	2,314.50	556.06	565.51	\$79.28	21.45
1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,		a) Professional obsesses	196.84	9.46	13.58	50.90	196.84	9.46	13 58	50.00
50 Charter comparison of the companient to the		Clinical actabilishment face	994.15	976.03	987.14	4,016.39	991.04	968.27	69'8'66	3 983 18
1,0 0 0 0 0 0 0 0 0 0		g) Denreciation and amortization acrosses	238.54	520.43	98.015	2,114.99	238.54	520.43	510.86	2 114 99
Total Compensation State Sta		h) Other expenses	302.22	114.14	107.41	438.31	302.22	114.14	107.41	438 31
Section Sect		Total expenses	663.38	751.69	715.71	2,916.96	664.07	752.21	716.01	2.918.38
Front from ordinary activities before tax (1-2) (184.91) 57.36 (99.12) 235.99 (175.89) 66.42 (87.89) 1.28 Fax expense Fax expense (51.44) (11.89) (29.43) (29.43) (29.43) (29.43) (48.93) (14.24) (26.51) (26.51) Fax expense Fax expense Fax expense (13.44) (13.44			3,623.86	3,773.39	3,674.43	15,191.84	3,624.14	3,774.85	3,673.83	15,191.40
14.24 11.89 (29.43) (48.93) 14.24 (26.51)	,		(184.91)	57.36	(99.12)	235.99	(175.89)	66.42	(87.89)	279.07
Net profit from ordinary activities after tax (3-4)	1		(51.44)	68.11	(29.43)	62.32	(48.93)	14.24	(26.51)	73.52
Hems that will not be reclassified subsequently to the statement of profit and loss: (a) Remeasurements of the defined benefit plans (b) Income tax relating to items that will not be reclassified to profit or 1.3.7 (b) Income tax relating to items that will not be reclassified to profit or 1.3.7 (c) Income tax relating to items that will not be reclassified to profit or 1.3.7 (c) Income tax relating to items that will not be reclassified to profit or 1.3.7 (c) Income tax relating to items that will not be reclassified to profit or 1.3.7 (c) Income tax relating to items that will not be reclassified to profit or 1.3.7 (c) Income tax relating to items that will not be reclassified to profit or 1.3.7 (c) Income tax relating to items that will not be reclassified to profit or 1.3.7 (c) Income tax relating to items that will not be reclassified to profit or 1.3.7 (c) Income tax relating to items that will not be reclassified to profit or 1.3.7 (c) Income tax relating to items that will not be reclassified to profit or 1.3.7 (c) Income tax relating to items that will not be reclassified to profit or 1.3.7 (c) Income tax relating to items that will not be reclassified to profit or 1.3.7 (c) Income tax relating to items that will not be reclassified to profit or 1.3.7 (d) Income tax relating to 1.3.7 (d) Income tax relating to 1.3.7 (d) Income tax relating tax relating to 1.3.7 (d) Income tax relating ta	W.		(133.47)	45.47	(69.69)	173.67	(126.96)	52.18	(61.38)	205.55
(a) Remeasurements of the defined benefit plans (b) Income tax relating to items that will not be reclassified to profit or loss (b) Income tax relating to items that will not be reclassified to profit or loss (c) Income tax relating to items that will not be reclassified to profit or loss (c) Income tax relating to items that will not be reclassified to profit or loss (c) Income tax relating to items that will not be reclassified to profit or loss (c) Income tax relating to items that will not be reclassified to profit or loss (c) Income tax relating to items that will not be reclassified to profit or loss (c) Income tax relating to items that will not be reclassified to profit or loss (c) Income tax relating to items that will not be reclassified to profit or loss (c) Income tax relating to items that will not be reclassified to profit or loss (c) Income tax relating to items that will not be reclassified to profit or loss (c) Income tax relating to items that will not be reclassified to profit or loss (c) Income tax relating to items that will not be reclassified to profit or loss (c) Income tax relating to items that will not be reclassified to profit or loss (c) Income tax relating to items that will not be reclassified to profit or loss (c) Income tax relating to items that will not be reclassified to profit or loss (c) Income tax relating to items that will not be reclassified to profit or loss (c) Income tax relating to items that will not be reclassified to profit or loss (c) Income tax relating to items that will not be reclassified to profit or loss (d) Income tax relating to items that will not be reclassified to profit or loss (d) Income tax relating to items that will not be reclassified to profit or loss (d) Income tax relating to items that will not be reclassified to profit or loss (d) Income tax relating to the company or loss (d) Income tax relating that the loss of the company or loss that the loss of the loss		Items that will not be reclassified subsequently to the statement of profit and loss:								
1.26 (1.44) (4.29) 4.38 (1.68) (1.44) (4.29) 4.38 (1.68) (1.44) (4.29) 4.38 (1.68) (1.44) (4.29) 4.38 (1.68) (1.44) (4.29) 4.38 (1.68) (1.44) (4.29) 4.38 (1.68) (1.44) (4.29) 4.38 (1.68) (1.44) (4.29) (4.28) (4.29)		(a) Remeasurements of the defined benefit plans (b) Income tax relating to items that will not be reclassified to profit or		4.53	13.82	15.41	(15.74)	6.15	13.82	17.03
Ottop comprehensive income / (loss) (net of tax)		loss		(1.26)	(1.44)	(4.29)	4 38	(891)	0.45	
Total Comprehensive Income for the period /year (5+6) (144.83) 48.74 (57.31) 184.79 (138.32) 56.65 (49.00) (144.83) (138.32) 56.65 (49.00) (144.83) (138.32)	0 1		(11.36)	3.27	12.38	11.12	(11.36)	447	12 38	(4./1)
-Owners of the company -Non-controlling interests Paid up equity share capital (face value Rs.10 each) - (Not Reserves excluding revaluation reserves Earnings Per Share (EPS) based on (5) above (of Rs. 10 each) - (Not annualised in the quarters) (0.71) O.25 (0.37) O.26 (138.32) 1,875.70 1,869.95 1,875.70 1,869.95 1,869.95 1,869.95 1,869.95 1,869.95 1,869.95 1,869.95 1,869.95 1,869.95 1,869.95 1,869.95 1,869.95 1,869.95 1,869.95 1,869.95 1,869.95 1,869.95 1,869.95 1,869.95 1,875.70 1,869.95 1,869.95 1,869.95 1,869.95 1,875.70 1,869.95 1,869.95 1,875.70 1,869.95 1,869.95 1,875.70 1,869.95 1,875.70 1,869.95 1,869.95 1,869.95 1,869.95 1,869.95 1,869.95 1,875.70 1,869.95 1,869.95 1,869.95 1,869.95 1,869.95 1,869.95 1,869.95 1,869.95 1,869.95 1,869.95 1,869.95 1,875.70 1,869.95	-		(144.83)	48.74	(57.31)	184.79	(138.32)	26.65	(49.00)	217.87
Paid up equity share capital (face value Rs. 10 each) - (Not annualised in the quarters) - Nan-Controlling interests Reserves excluding revaluation reserves Reserves excluding revaluation reserves - Basic - Controlling interests NA N		- Owners of the company	NA	NA	NA	NA	(138 32)	39 95	(40 00)	200
Reserves excluding revaluation reserves NA NA NA NA NA NA NA NA NA N	o	Poid in controlling interests	. NA	NA	NA	NA		0.00	(42.00)	78./17
Earnings Per Share (EPS) based on (5) above (of Rs. 10 each) - (Not annualised in the quarters) - Basic - Diluted - Diluted - Diluted - Diluted - Diluted - Diluted - Dilut	0	Reserves excluding revoluction recent	1,875.70	1,875.70	1,869.95	1,875.70	1,875.70	1,875.70	1,869.95	1 875 70
(0.71) 0.25 (0.37) 0.93 (0.68) 0.28 (0.33) (0.71) 0.94 (0.37) 0.92 (0.68) 0.27 (0.33)	9		VA	AN	NA	8,483.73	NA	NA	NA	8,661.91
$ \begin{array}{c ccccc} (0.71) & 0.25 & (0.37) & 0.93 & (0.68) & 0.28 & (0.33) \\ \hline & (0.71) & 0.24 & (0.37) & 0.92 & (0.68) & 0.27 & (0.33) \\ \hline \end{array} $		annualised in the quarters)								
(0.71) 0.24 (0.37) 0.92 (0.68) 0.71 (0.13)		- Basic	(0.71)	0.25	(0.37)	0 03	(89 0)	000	111.00	
0.00		- Diluted	(0.71)	0.24	(0.37)	0.92	(0.03)	0.28	(0.33)	1.10



R & Co.





FORTIS MALAR HÓSPITALS LIMITED (CIN: L85110PB1989PLC045948) Regd. Office: Fortis Hospital, Sector 62, Phase – VIII, Mohali-160062 Tel Numbers: 0172 5096001 & Tele Ray No. 1072 5096002

Website: www.fortismalar.com; Email: secretarial.malar@malar.hospitals.in
STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30-JUNE-2019

- The unaudited standalone and consolidated financial results for the quarter ended 30 June 2019 has been reviewed by the Audit and Risk Management Committee and subsequently approved by the Board of report. Further, the consolidated financial result for the corresponding quarter ended 30 June 2018 and quarter ended 31 March 2019, as reported in these financial results have been approved by Audit and Risk Directors at their respective meeting held on 2 August 2019. The above results have been subjected to limited review by the Statutory auditors of the Company. The auditors have issued an unmodified review Management Committee and subsequently approved by the Board of Directors at their respective meeting held on 2 August 2019, but have not been subjected to limited review by the Statutory auditors of the
- 2 These unaudited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 The consolidated financial results includes the financial results of the Company Fortis Malar Hospitals Limited and the financial results of its subsidiary company Malar Stars Medicare Limited (collectively known as "Group")
- 4 The Company is engaged in the Healthcare Services, which in the context of Indian Accounting Standard (Ind AS) 108 Operating Segments is considered as the only reportable segment of the Company.
- 5 The standalone figures for the quarter ended 31 March 2019 are the balancing figures between the audited standalone figures in respect of the full previous financial year and the published unaudited year to date standalone figures upto the end of the third quarter of the previous financial year, which were subjected to limited review.
- date of initial application, at the present value of the remaining lease payments discounted using the incremental borrowings rate at the date of initial application, recognized right-of-use asset at the date of initial application equals to the lease liability recognized and the comparatives have not been retrospectively adjusted. In the profit and loss for the current period, the lease rent which was hitherto accounted under 5 The Company has adopted Ind AS 116 - Leases, with the date of initial application being 1 April 2019, using the modified retrospective approach. Accordingly, the Company has recognized a lease liability at the clinical establishment expenses/other expenses in the previous periods has now been accounted as depreciation charge for the right-of-use asset and finance cost for interest accrued on lease liability. Accordingly, the profit for the current quarter is lower by Rs. 76.99 lakhs (net of deferred tax created).
- March 2016, CMDA has issued an Order stating that the regularization application made by the Company has not been allowed. The Company had preferred an appeal before the Secretary to the Government of Tamil Nadu, Housing and Urban Development Authority against the said Order. On 03 May 2016 CMDA has also served a Locking & Sealing and De-occupation Notice to the Company stating that in view of directed by the Hon'ble High Court, CMDA Officials inspected the hospital premises and directed the Company to provide ramp facility for easy evacuation of patients. The Company has ramped up its fire CMDA's Order dated 18 March 2016 referred above, the construction at the site of the Hospital premises is unauthorized and has called upon the Company to restore the land to its original position within 30 days from the date of the Notice. The Company appealed to the High Court of Judicature at Madras and obtained a stay order on 02 June 2016 directing CMDA not to proceed further, till the matter is disposed. As 7 The Company had in earlier years applied to the Chennai Metropolitan Development Authority (CMDA) for regularization of certain deviations in the construction of the Hospital. During the year ended 31 detection and safety measures, constructed horizontal walkways and also obtained a Certificate from an independent agency on the adequacy of measures taken for fire prevention and safety. The Company, based on legal advice, believes that the above Order / Notices issued by CMDA are contestable and the same prima facie would not result in adverse impact on it's operations/ going concern as the Company has fair chance of success in the aforesaid Appeal / writ petition.
- 8 Figures for the prior periods / year have been reclassified/ regrouped wherever required to conform to the classification of the current period.
- 9 These financial results are available on the BSE website (www.bseindia.com) and on the Company's website (www.fortismalar.com).



P. Murari Chairman Chairman DIN No. 00020437

3

For and on behalf of Board of Directors of Fortis Malar Hospitals Limited

By Order of the Board

Place: Chennai Date : 2 August 2019

BSR&Co.LLP

Chartered Accountants

KRMTower, 1st & 2nd Floor, No.1, Harrington Road, Chetpet, Chennai - 600 031, India. Telephone : +91 44 4608 3100 Fax : +91 44 4608 3199

Limited review report on unaudited quarterly standalone financial results of Fortis Malar Hospitals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To Board of Directors of Fortis Malar Hospitals Limited

- 1. We have reviewed the accompanying Statement of unaudited standalone financial results of **Fortis Malar Hospitals limited** ("the Company") for the quarter ended 30 June 2019 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
- 2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2019 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
- 5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



Limited review report on unaudited quarterly standalone financial results of Fortis Malar Hospitals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Page 2 of 2

6. The figures for the quarter ended 30 June 2018 included in these financial results were reviewed by the predecessor auditor who expressed an unmodified opinion vide their limited review report dated 31 July 2018. Our conclusion on the statement is not modified in respect of the above matter.

for B S R & Co. LLP

Chartered Accountants

Firm's Registration No. 101248W/W-100022

Amar Sunder

Partner

Membership No. 078305

UDIN: 19078305AAAACA7577

Place: Chennai

Date: 2 August 2019

BSR&Co.LLP

Chartered Accountants

KRM Tower, 1st & 2nd Floor, No 1, Harrington Road, Chetpet, Chennai - 600 031, India. Telephone +91 44 4608 3100 Fax +91 44 4608 3199

Limited review report on unaudited quarterly consolidated financial results of Fortis Malar Hospitals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To Board of Directors of Fortis Malar Hospitals Limited

- 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Fortis Malar Hospitals limited ("the Parent") and its subsidiary Company (the Parent and its subsidiary Company together referred to as "the Group") for the quarter ended 30 June 2019, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'). Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 30 June 2018 and quarter ended 31 March 2019, as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review, since the requirement of submission of quarterly consolidated financial results has become mandatory only from 1 April 2019.
- 2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the subsidiary Company, Malar Stars Medicare Limited.



Limited review report on unaudited quarterly consolidated financial results of Fortis Malar Hospitals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Page 2 of 2

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

for BSR & Co. LLP

Chartered Accountants

Firm's Registration No. 101248W/W-100022

Amar Sunder

Partner

Membership No. 078305

UDIN.: 19078305AAAACB3515

Place: Chennai

Date: 2 August 2019



FORTIS MALAR REPORTS Q1FY20 CONSOLIDATED REVENUE AT RS 31.87 CR OPERATING PROFIT FOR THE QUARTER AT RS.0.62 CR

Chennai, August 2, 2019: Fortis Malar Hospitals Limited, a subsidiary of Fortis Healthcare Limited, a leading integrated healthcare delivery provider in India, today announced its results for the quarter ended June 30, 2019.

Commenting on the results Mr.P.Murari, Chairman, Fortis Malar Hospitals Limited, said, "Fortis Malar is known for performing high end complex surgical work across various specialties such as Cardiology, Neurology and Mother & Child care. The team of doctors at Fortis Malar has been doing some exceptional clinical work through which Fortis Malar has achieved the unique distinction of conducting over 300 Thoracic organ transplants, reinforcing its position as a world class super specialty tertiary care centre. I am quite delighted with the great work being performed by our team of doctors, nurses, paramedics and other staff members and am confident that we will continue to deliver world class clinical treatment with consistently superior clinical outcomes in the future, as well."

Financial Highlights (consolidated) for the Quarter (Q1FY20)

- Fortis Malar Hospitals reported operating revenue of Rs 31.87 Cr compared to Rs 33.56 Cr reported in the corresponding quarter of the previous year.
- Operating profit / (loss) for the quarter stood at Rs (1.69) Cr [with the impact of Ind AS -116 profit stood at Rs.0.62 Cr] compared to Rs (1.97) Cr in the corresponding quarter of previous year.
- Profit before tax stood at Rs.(0.69) Cr [with the impact of Ind AS 116 PBT stood at Rs.(1.76) Cr] compared to Rs. (0.88) Cr in corresponding guarter of previous year.
- Net profit for the quarter was at Rs (0.50) Cr [with the impact of Ind AS 116 Profit stood at Rs.(1.27) Cr] compared to Rs.(0.61) Cr in corresponding quarter of previous year.
- Revenue from Gynecology grew by 24% and other specialties such as Pulmonology and MSOT grew by 52% & 14% respectively compared to the corresponding quarter of previous year.

Operational Highlights for the Q1FY20

- Fortis is Malar Hospital Celebrated World Health Day, Emphasizes Daily Exercise for Long Life Celebrating World Health Day, Fortis Malar Hospital conducted a unique camp to promote healthy living. The session organized at Nageshwara Rao Park, Mylapore saw doctors from Fortis Malar providing training on basic exercises to participants from across different age groups. Physiotherapist Mr Khashif, Fortis Malar Hospital, gave guidance to elderly walkers on basic exercises and motions to increase the body's mobility and reduce joint and muscle injury. Mr. R Picchiah Kasinathan, Senior Dietician, Fortis Malar Hospital gave advice on foods that people can include in their diet to improve health and daily energy.
- Two-Year-old donor donates heart to save life of a two-year-old
 Fortis Malar Hospital successfully conducted a unique heart transplant surgery to save the life of two-year-old Rohan (name changed) from Villupuram. This became possible after Rohan received the





heart from the country's youngest organ donor – a two-year-old boy from Mumbai. The transplant was performed by a team of doctors led by Dr. K R Balakrishnan, Director, Cardiac Sciences, Fortis Malar Hospital and Dr. Suresh Rao KG, Head of Department, Critical Care & Cardiac Anaesthesia, Fortis Malar Hospital.

- Fortis Malar Educates Fire and Rescue Services Department on Stress Management
 Fortis Malar Hospital organized an awareness program on hypertension for the members of Fire and
 Rescue Services of Tamil Nadu. On the occasion of World Hypertension Day, over 50 members took
 part in the session and enthusiastically participated in a blend of cathartic activities that were
 organised to manage stressful situations. The event was launched by Mr. Selvam, Station Officer,
 Tamil Nadu Fire and Rescue Service, Guindy and Ms. Sneha George, Counselling Psychologist, Fortis
 Malar Hospital. A medical camp was set up at the premises of the Fire and Rescue Services wherein
 members of the department underwent standard health tests including blood pressure analysis.
- Septuagenarian Woman Walks after successfully treated for a Complex Hip Surgery at Fortis Malar Hospital
 A team of doctors at Fortis Malar Hospital successfully performed a successful complex Revision Total Hip Replacement surgery on a 76-year-old patient recently. The patient Ms. Pankajavalli developed periprosthetic hip fracture a few weeks after undergoing a partial hip replacement surgery at another private hospital in the city. The team was led by Dr. Nandkumar Sundaram, Orthopaedic Surgeon, Fortis Malar Hospital.
- Fortis Malar creates awareness on "Safe blood for all" on World Blood Donors Day
 As a part of World Blood Donor Day, Fortis Malar Hospital organised an awareness session on the
 need for blood donation and felicitated voluntary blood donors who have been regularly donating
 blood. The session began with Dr. Jyotsna Codaty, HOD, Transfusion Medicine, Fortis Malar Hospital
 who shared insights on "Safe blood for all". Dr Suresh Rao KG, Head of Department, Critical Care &
 Cardiac Anaesthesia, Fortis Malar Hospital and Dr. Nithya Ramamurthy, Senior Consultant,
 Gynaecology, Fortis Malar Hospital threw light and educated the participants on how transfusion of
 blood and blood products play a significant role in surgeries and saving lives.
- Fortis Malar Hospital recommends yoga for a healthy mind
 This International Yoga Day, Fortis Malar Hospital in association with GTA Vidhya Mandir conducted
 an exclusive session on 'Yoga and Mental Health' with 200 school students performing yoga at GTA
 Vidhya Mandir School, Neelankarai. The session was presided by Ms. Sneha George, Counselling
 Psychologist, Fortis Malar Hospital and Mr. A Murugan, MallarKambam Association Coach,
 Tamilnadu, GTA Vidhya Mandir School, Neelankarai. Ms. Sneha enlightened the students (between
 the ages of 8 to 12 years) on the numerous benefits of yoga for a healthy mind. Mr. A Murugan
 taught the school children various yoga poses, breathing and meditation exercises for improved
 mental wellbeing.
- World Milk Day Fortis Malar and Cavin's educates expectant mothers on the benefits of Milk On the occasion of World Milk Day 2019, young mothers-to-be from different parts of the city gathered together at Fortis Malar Hospital for a special awareness talk on the benefits of consuming milk during different stages of pregnancy. Organized by Chennai's leading healthcare provider, Fortis Malar, along with Cavin's, the dairy arm of FMCG giant CavinKare, the specially curated session was helmed by Dr. Nithya Ramamurthy, Senior consultant, Gynaecology, Fortis Malar Hospital, and Dr. Meenakshi Narayanan, Head – R&D, CavinKare. This one-of-a-kind session was also followed by an exciting baby shower put together by the hospital to celebrate and cherish the expectant mothers.





About Fortis Malar Hospitals Ltd

Fortis Malar Hospital (formerly known as Malar Hospital) was acquired by Fortis Healthcare (India) Limited in early 2008. The hospital founded in 1992, is established as one of the largest corporate hospitals in Chennai providing quality super specialty and multi-specialty healthcare services. Fortis Malar Hospitals, with 180 beds, focuses on providing comprehensive medical care in the areas of Cardiology and Cardiac Surgery, Neuro Surgery, Gynecology, Orthopedics, Gastroenterology, Neurology, Pediatrics, Diabetics, Nephrology and Internal Medicine.

Fortis Malar Hospital has a state of the art Cath Lab and multiple dedicated cardiac operation theatres and intensive coronary care units. Several rare and complex Adult and Paediatric Cardiac surgeries, Orthopedic and Joint replacements, Neurosurgeries and Plastic reconstruction surgeries have been performed at this hospital. The hospital's Obstetrics and Gynaecology services are among the busiest in the city, successfully performing many complicated deliveries and surgeries. They are supported by a dedicated Neonatology unit.

About Fortis Healthcare Ltd

Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Dubai and Sri Lanka with 40 healthcare facilities (including projects under development), approximately 9,000 potential beds and over 400 diagnostic centers.

DISCLAIMER

This press release may contain forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this press release are cautioned not to place undue reliance on these forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this press release, without obligation to notify any person of such revision or changes.

FOR MORE INFORMATION PLEASE CONTACT

Rokesh A PR & Communications Fortis Malar Hospitals Ltd Mobile:8667867754

rokesh.a@fortishealthcare.com